ClearPoint's drug delivery platform bets on partner CGT approvals by 2027, but a Q3 2027 cash cliff arrives before those approvals are confirmed

ClearPoint Neuro is a commercial-stage medical device company selling FDA-cleared neurosurgical navigation and drug-delivery hardware, which biopharma partners use to deliver their own cell and gene therapies -- none of those partner therapies are approved yet.

ClearPoint Neuro provides MRI-guided neurosurgical navigation and intracranial drug delivery infrastructure used by biopharma partners advancing cell and gene therapies for rare brain diseases. The thesis resolves on whether multiple partner BLAs clear FDA by end of 2027, converting service revenue into a durable royalty stream before the Q3 2027 cash runway expires. The principal risk is a funding gap: at $7.5M quarterly burn and $29M cash, the company reaches its runway limit roughly concurrent with the earliest partner approvals, leaving no margin for regulatory delay.